Remove 2030 Remove Packaging Remove Treatment
article thumbnail

reporting continued progress towards elimination as a public health problem

The Pharma Data

billion cumulative treatments to more than 923 million people since 2000. The treatments target the parasites in the blood of infected people and prevent the risk of transmission in the community. Setting sights on 2030. Despite setbacks due to COVID-19, WHO will accelerate work to achieve this target by 2030.

article thumbnail

Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines

The Pharma Data

Additionally, Sanofi is committed to helping 1,000 patients living with rare diseases who have no access to treatments and will donate 100,000 vials of medicine for their treatments each year. Leveraging R&D efforts to address crucial treatment gaps. Zero plastic packaging for vaccines and ecodesign of products.

Vaccine 52
article thumbnail

Analysis Chemical Thank You How states are looking to control PFAS through different legislative models

Agency IQ

In general, the law also pushes out a prohibition on almost all products with intentionally added PFAS from January 2030 to January 2032 , except for some cooling, heating, and refrigerant products which will be allowed until 2040.

article thumbnail

The Forgotten Pandemic

Codon

In 2014, the World Health Organization (WHO) proposed an initiative called the End TB Strategy , aimed at reducing cases by 80 percent, deaths by 90 percent, and diagnostic/treatment costs by 100 percent by 2030. In The Magic Mountain , patients receiving this treatment joined what they dubbed the “Half-Lung Club.”

article thumbnail

Article Periodic Thank You Why comprehensive state-level bans on PFAS in products are faltering

Agency IQ

In addition, the law prohibits the sale of carpets or fabric treatments containing PFAS as of January 1, 2023. In 2030, the law will ban the use of any product with intentionally added PFAS, unless the Maine legislature determines that the product currently serves an unavoidable use.

article thumbnail

Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results

The Pharma Data

CDMO Services assumes continued growth in Development Services (DVS), Drug Substance (DS) manufacturing, and Drug Product (DP) manufacturing and Packaging for both clinical- and commercial-stage projects on behalf of a growing list of pharmaceutical and biotechnology innovators and government/NGO customers. FOOTNOTES. (1)

article thumbnail

Regeneron Reports Third Quarter 2020 Financial and Operating Results

The Pharma Data

Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.” ” “We continue to invest in our promising pipeline while delivering meaningful revenue and earnings growth.